The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.40
Ask: 19.65
Change: 0.00 (0.00%)
Spread: 1.25 (6.793%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.65
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

2 Jul 2012 07:00

RNS Number : 5826G
BATM Advanced Communications Ld
02 July 2012
 



 

 

 

2 July 2012

 

BATM Advanced Communications Limited

("BATM" or "the Company")

AGM Statement

The following statement will be made by Peter Sheldon, Chairman of BATM, at the Company's Annual General Meeting being held today at 11.00am:

 

 "I would like to provide a business and trading update for the six months to 30 June 2012 ahead of our interim results to be announced in August 2012.

 

"2012 is very much a transitional year for BATM. During the first half, the Company completed the restructuring of its telecoms division and is now focused on growing this business following the decline of Nokia Siemens Networks ("NSN") business. For the medical division, the Company has been focused on expanding its distribution business, supporting the growth of its sterilization business and continuing to invest significantly in achieving more CE certifications for its diagnostics business.

 

"For the first half of 2012 ("H1"), the Company expects to announce total revenues broadly in line with management expectations of approximately $52m compared with $56m for the equivalent period in 2011 (on a like for like basis and excluding revenues from the discontinued legacy telecom business).

 

"Turning to the performance of the two divisions specifically, the telecoms business will show an approximate 20% decline in revenues compared with the equivalent period in 2011, which is marginally lower than management expectations. The expected 66% decline in OEM revenues from NSN will be partially offset by a 15% increase over the same period last year in the direct IP business in the US as well as initial contributions from two new OEM agreements signed in the last quarter of 2011.

 

"The medical business is expected to show better than anticipated revenues, with an increase of approximately 15% over the equivalent period last year, due to growth throughout the division, including initial contributions from the diagnostics business as a result of achieving CE certification, announced in March and May 2012, for two products.

 

"The blended gross margin is expected to be approximately 34% in H1 compared with 39% for the same period of 2011. This is due to a greater contribution to sales from the medical division and slightly lower than expected revenues in the telecoms division. As a consequence of this and the continued investment into the diagnostics business, we now expect the Company to show a breakeven position for the first half rather than a small operating profit as was originally anticipated. In the second half of 2012, operating profit is anticipated to be breakeven at the third quarter and return to profitability from the beginning of the fourth quarter 2012.

 

 "Looking ahead, the telecoms division is expected to return to growth following the completion of our relationship with NSN, while the medical division is expected to become profitable and will see growth in both revenues and margins going forward. The Board believes we are on track to achieve our strategic targets for the full year 2012 and remain optimistic about delivering shareholder value in the medium term.

 

"Finally, an update on the impending dual listing on TASE. We are making good progress and are in the final stages of the process and anticipate conclusion to occur in August 2012 with shares commencing trading before September 1st 2012."

 

- Ends -

 

Enquiries

 

BATM Advanced Communications +972 9866 2525   

Dr Zvi Marom, Chief Executive

Ofer Bar-Ner, CFO

 

Newgate Threadneedle 020 7653 9850

Josh Royston / Graham Herring

 

finnCap 020 7220 0500

Marc Young

 

Shore Capital 020 7408 4090 

Pascal Keane

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUAUVRUBABRAR
Date   Source Headline
2nd May 20247:00 amRNSBATM selected for TB diagnostics programme
18th Apr 20247:00 amRNSBATM to deliver Edgility to new Tier 1 customer
8th Apr 20247:00 amRNSBATM awarded new Edgility contract from Cemex
3rd Apr 20247:00 amRNSAnnual Financial Report
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.